Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph Kambeitz

Showing results (121-130 of 132) with videos related to

Pageof 14
Sort By:
Early Intervention in Psychiatry|August 29, 2023
Development of the PSYCHS: Positive SYmptoms and Diagnostic Criteria for the CAARMS Harmonized with the SIPSScott W Woods, Sophie Parker, Melissa J Kerr, et al.
Schizophrenia Bulletin Open|July 16, 2026
Relationship among Sleep Disturbance, Stress, and Suicidal Ideation in Clinical High Risk for PsychosisHeather M Wastler, Aubrey Moe, Alexandra M Blouin, et al.
Schizophrenia Bulletin Open|August 27, 2025
Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia ProgramJean Addington, Lu Liu, Monica Chu, et al.
Schizophrenia (Heidelberg, Germany)|October 15, 2025
Collecting language, speech acoustics, and facial expression to predict psychosis and other clinical outcomes: strategies from the AMP® SCZ initiativeZarina R Bilgrami, Eduardo Castro, Carla Agurto, et al.
Schizophrenia Bulletin Open|August 27, 2025
Sample Ascertainment and Recruitment Sources in the Accelerating Medicines Partnership Schizophrenia ProgramJean Addington, Amy Shalev, Lu Liu, et al.
Schizophrenia (Heidelberg, Germany)|April 3, 2025
Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia ProgramJean Addington, Lu Liu, Amy Braun, et al.
Schizophrenia Bulletin|May 11, 2026
Premorbid adjustment problems, negative symptoms, and cognitive impairment in a large international sample at clinical high risk for psychosis: Findings from the Accelerating Medicines Partnership-SchizophreniaHenry R Cowan, Danielle Pratt, Jai L Shah, et al.
Schizophrenia (Heidelberg, Germany)|April 2, 2025
The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia ProgramMichael P Harms, Kang-Ik K Cho, Alan Anticevic, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 3, 2022
Chronic neuropsychiatric sequelae of SARS-CoV-2: Protocol and methods from the Alzheimer's Association Global ConsortiumGabriel A de Erausquin, Heather Snyder, Traolach S Brugha, et al.
Schizophrenia (Heidelberg, Germany)|March 25, 2025
Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sampleKelly Allott, Walid Yassin, Luis Alameda, et al.
Pageof 14

Showing results (121-130 of 132) with videos related to

Sort By:
Pageof 14
Early Intervention in Psychiatry|August 29, 2023
Development of the PSYCHS: Positive SYmptoms and Diagnostic Criteria for the CAARMS Harmonized with the SIPSScott W Woods, Sophie Parker, Melissa J Kerr, et al.
Schizophrenia Bulletin Open|July 16, 2026
Relationship among Sleep Disturbance, Stress, and Suicidal Ideation in Clinical High Risk for PsychosisHeather M Wastler, Aubrey Moe, Alexandra M Blouin, et al.
Schizophrenia Bulletin Open|August 27, 2025
Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia ProgramJean Addington, Lu Liu, Monica Chu, et al.
Schizophrenia (Heidelberg, Germany)|October 15, 2025
Collecting language, speech acoustics, and facial expression to predict psychosis and other clinical outcomes: strategies from the AMP® SCZ initiativeZarina R Bilgrami, Eduardo Castro, Carla Agurto, et al.
Schizophrenia Bulletin Open|August 27, 2025
Sample Ascertainment and Recruitment Sources in the Accelerating Medicines Partnership Schizophrenia ProgramJean Addington, Amy Shalev, Lu Liu, et al.
Schizophrenia (Heidelberg, Germany)|April 3, 2025
Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia ProgramJean Addington, Lu Liu, Amy Braun, et al.
Schizophrenia Bulletin|May 11, 2026
Premorbid adjustment problems, negative symptoms, and cognitive impairment in a large international sample at clinical high risk for psychosis: Findings from the Accelerating Medicines Partnership-SchizophreniaHenry R Cowan, Danielle Pratt, Jai L Shah, et al.
Schizophrenia (Heidelberg, Germany)|April 2, 2025
The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia ProgramMichael P Harms, Kang-Ik K Cho, Alan Anticevic, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 3, 2022
Chronic neuropsychiatric sequelae of SARS-CoV-2: Protocol and methods from the Alzheimer's Association Global ConsortiumGabriel A de Erausquin, Heather Snyder, Traolach S Brugha, et al.
Schizophrenia (Heidelberg, Germany)|March 25, 2025
Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sampleKelly Allott, Walid Yassin, Luis Alameda, et al.
Pageof 14